Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jaliffe GG, Cicin I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, André V, Harbeck N, Martin M; monarchE Committee Members. Johnston SRD, et al. Among authors: neven p. Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6. Lancet Oncol. 2023. PMID: 36493792 Clinical Trial.
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Regan MM, et al. Among authors: neven p. Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20. Lancet Oncol. 2011. PMID: 22018631 Free PMC article. Clinical Trial.
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.
Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart M, Harbeck N. Schuler M, et al. Among authors: neven p. Breast Cancer Res Treat. 2012 Aug;134(3):1149-59. doi: 10.1007/s10549-012-2126-1. Epub 2012 Jul 5. Breast Cancer Res Treat. 2012. PMID: 22763464 Free PMC article. Clinical Trial.
Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study.
Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Van Calster B, Loibl S. Amant F, et al. Among authors: neven p. J Clin Oncol. 2013 Jul 10;31(20):2532-9. doi: 10.1200/JCO.2012.45.6335. Epub 2013 Apr 22. J Clin Oncol. 2013. PMID: 23610117
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.
Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA 3rd. Campone M, et al. Among authors: neven p. Curr Med Res Opin. 2013 Nov;29(11):1463-73. doi: 10.1185/03007995.2013.836078. Epub 2013 Sep 4. Curr Med Res Opin. 2013. PMID: 23962028 Clinical Trial.
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.
Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG); Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO); Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO); National Cancer Research Institute (NCRI); Australia New Zealand Gynaecological Oncology Group (ANZGOG); Mario Negri Gynecologic Oncology group (MaNGO). Despierre E, et al. Target Oncol. 2015 Dec;10(4):583-96. doi: 10.1007/s11523-015-0369-6. Target Oncol. 2015. PMID: 26004768 Free PMC article. Clinical Trial.
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Li W, O'Shaughnessy J, Hayes D, Campone M, Bondarenko I, Zbarskaya I, Brain E, Stenina M, Ivanova O, Graas MP, Neven P, Ricci D, Griffin T, Kheoh T, Yu M, Gormley M, Martin J, Schaffer M, Zelinsky K, De Porre P, Johnston SR. Li W, et al. Among authors: neven p. Clin Cancer Res. 2016 Dec 15;22(24):6002-6009. doi: 10.1158/1078-0432.CCR-15-2452. Epub 2016 Jun 7. Clin Cancer Res. 2016. PMID: 27267854 Clinical Trial.
Combined modality adjuvant therapy for high-risk endometrial cancer.
Vanderstichele A, Neven P, Vergote I. Vanderstichele A, et al. Among authors: neven p. Lancet Oncol. 2016 Aug;17(8):1029-1030. doi: 10.1016/S1470-2045(16)30152-8. Epub 2016 Jul 7. Lancet Oncol. 2016. PMID: 27397044 Free article. No abstract available.
544 results